Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies

Lawrence Eichenfeld,Michael Kuligowski,Kang Sun,Eric Simpson,Leon Kircik,Andrew Blauvelt,May Venturanza

doi:10.25251/skin.5.supp.66

Abstract

N/A

Highlights

Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies
– For patients with more severe Atopic dermatitis (AD), systemic therapies may be considered as monotherapy or in combination with topical therapies[6]
● Ruxolitinib cream is a topical formulation of ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1/JAK27

Summary

Introduction

● The severity of AD is often stratified using objective (Investigator’s Global Assessment [IGA], Eczema Area and Severity Index [EASI], body surface area [BSA]) and subjective (eg, itch numerical rating scale [NRS]) assessment tools[2,3,4]. – For patients with more severe AD, systemic therapies may be considered as monotherapy or in combination with topical therapies[6]. – Failure of topical therapies represents one factor when considering systemic therapy; it is not known whether new, more effective nonsteroidal therapies could prevent some patients from starting systemic therapy. ● Ruxolitinib cream is a topical formulation of ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1/JAK27. ● In two phase 3 randomized studies of identical design (TRuE-AD1 [NCT03745638] and TRuE-AD2 [NCT03745651]), ruxolitinib cream demonstrated anti-inflammatory activity with antipruritic action vs vehicle and was well tolerated in patients with AD7

Methods

Results

Conclusions

Disclosures